|Articles|June 29, 2018
Korean Biotech Talks About U.S. Company Launch
Author(s)Michelle Maskaly
Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
Advertisement
Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
He spoke to Pharm Exec during a company event in New York City.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
2
Pharma Roundup: Mounjaro Shows Advantages in Type 2 Diabetes, Immune System Linked to Long Covid Symptoms
3
FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant
4
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
5